Published 28th September 2017

PsiOxus featured in FierceBiotech's Fierce 15

Portfolio company PsiOxus has been featured in the 2017 edition of FierceBiotech's Fierce 15 list. 

Expanding on Psioxus' inclusion in the list, FierceBiotech emphasised its pipeline: its lead candidate, enadenotucirev, targets tumour cells, leaves healthy cells alone, and stays potent over time. Early data suggests the candidate drug can be delivered via the bloodstream, a much simpler method than directly to the tumour.

Fierce 15 is FierceBiotech's Special Report which focuses on the 15 companies it considers to combine the best science with the best and brightest management teams, and companies that have a genuine chance of being the Next Big Thing.

Read FierceBiotech's release